Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.25
Ask:
1.35
Spread: 0.10 (8.00%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Update on CFO Appointment

29 Nov 2016 07:00

RNS Number : 3503Q
Genedrive PLC
29 November 2016
 

 

 

For release: 29 November 2016

 

genedrive plc ("genedrive" or the "Company")

 

Update on CFO Appointment

 

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, is pleased to announce that, following his appointment as Chief Financial Officer and a Director of the Company as announced on 21 September 2016, Matthew Fowler will join genedrive plc on 13 December 2016.

 

Matthew joins genedrive plc with over 15 years of experience in senior positions in the manufacturing, power and support services industries. Prior to joining genedrive plc, Matthew spent eight years as Group Financial Controller of Scapa Group plc, a multinational manufacturing AIM-quoted business. At Scapa Group plc, Matthew was responsible for shaping and managing finance within the Group as well as strategy development and other core processes.

 

Before joining Scapa Group plc, Matthew spent three years at British Nuclear Group as Finance Manager where he managed the corporate centre's finance team and was responsible for planning, reporting and accounting. Matthew trained and qualified in the audit department of Deloitte & Touche.

- Ends -

 

For further details please contact:

genedrive plc

David Budd: CEO +44 (0)161 989 0245

 

Peel Hunt LLP

James Steel +44 (0)207 418 8900

Oliver Jackson

 

Consilium Strategic Communications

Chris Gardner +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

 

 

Notes to Editors

 

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

 

genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

 

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGGGUGUPQGMR
Date   Source Headline
21st May 20209:36 amRNSHolding(s) in Company
20th May 20203:38 pmRNSHolding(s) in Company
13th May 202010:26 amRNSHolding(s) in Company
12th May 20207:00 amRNSResults of Broker Option
7th May 20205:25 pmRNSHolding(s) in Company
7th May 20204:58 pmRNSPosting of shareholder circular
7th May 202011:05 amRNSSecond Price Monitoring Extn
7th May 202011:00 amRNSPrice Monitoring Extension
5th May 20206:24 pmRNSResult of Placing
5th May 20209:00 amRNSPrice Monitoring Extension
5th May 20208:50 amRNSProposed Placing and Broker Option
4th May 20205:00 pmRNSWHO Prequalification for Genedrive HCV-ID test
4th May 20202:05 pmRNSSecond Price Monitoring Extn
4th May 20202:00 pmRNSPrice Monitoring Extension
1st May 20202:05 pmRNSSecond Price Monitoring Extn
1st May 20202:01 pmRNSPrice Monitoring Extension
1st May 20207:00 amRNSManufacturing milestones met for SARS-CoV-2 test
29th Apr 20209:06 amRNSSecond Price Monitoring Extn
29th Apr 20209:00 amRNSPrice Monitoring Extension
28th Apr 20204:42 pmRNSSecond Price Monitoring Extn
28th Apr 20204:35 pmRNSPrice Monitoring Extension
28th Apr 20202:05 pmRNSSecond Price Monitoring Extn
28th Apr 20202:00 pmRNSPrice Monitoring Extension
27th Apr 20209:00 amRNSPrice Monitoring Extension
24th Apr 20203:30 pmRNSHolding(s) in Company
24th Apr 20207:00 amRNSDistribution agreement for AIHL test
24th Apr 20207:00 amRNSDistribution agreement for AIHL test
22nd Apr 20207:00 amRNSAppointment of Joint Broker
21st Apr 20204:41 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20202:52 pmRNSHolding(s) in Company
20th Apr 20209:05 amRNSSecond Price Monitoring Extn
20th Apr 20209:00 amRNSPrice Monitoring Extension
20th Apr 20207:00 amRNSCytiva collaboration on Coronavirus PCR Test
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:01 pmRNSPrice Monitoring Extension
16th Apr 20202:53 pmRNSHolding(s) in Company
15th Apr 20204:41 pmRNSSecond Price Monitoring Extn
15th Apr 20204:36 pmRNSPrice Monitoring Extension
15th Apr 20202:05 pmRNSSecond Price Monitoring Extn
15th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 20209:06 amRNSSecond Price Monitoring Extn
14th Apr 20209:00 amRNSPrice Monitoring Extension
14th Apr 20207:01 amRNSHolding(s) in Company
14th Apr 20207:00 amRNSHolding(s) in Company
31st Mar 202011:52 amRNSHolding(s) in Company
30th Mar 20202:01 pmRNSHolding(s) in Company
30th Mar 202011:06 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.